Download the 2026 Economic Impact Report
Join Now
Join Now

OsteoCure Therapeutics: Biologics Startup Chosen For SCbioDrive Accelerator Program

SOUTH CAROLINA – May 13, 2025 – OsteoCure Therapeutics, Inc. is a company that originated from Duke University and operates as a global life sciences network for innovation, focused on developing advanced therapies to address critical unmet bone health and regeneration needs. Leveraging cutting-edge research, the company specializes in novel combination products designed to accelerate bone healing, mitigate pain, improve patient outcomes and reduce recovery times for those suffering from orthopedic injuries and conditions. Operating within the rapidly evolving biotechnology and regenerative medicine industries, OsteoCure Therapeutics capitalizes on advancements in small-molecule and drug delivery technologies to pioneer new treatment modalities.

Solutions

OsteoCure Therapeutics’ OCTA1 leverages adenosine signaling, a novel approach utilizing the natural properties of adenosine to modulate inflammation, stimulate osteogenesis and rapidly alleviate bone-associated pain. This dual-action mechanism uniquely positions OCTA1 as an effective solution to manage severe bone pain while concurrently enhancing bone repair processes. OCTA1 fulfills the orthopedic surgeon’s needs in three distinct ways: i) OCTA1 is injectable, easy to use and customizable to the surgeon’s placement; ii) OCTA1 anneals in situ, resulting in a porous 3D structure to facilitate cell infiltration for healing; iii) OCTA1 delivers a therapeutic which simultaneously promotes bone healing and mitigates pain for the patient.

Strengths

  • Innovative Technology
    • OsteoCure Therapeutics’ proprietary product, OCTA1, uniquely accelerates bone regeneration and significantly reduces pain using a natural small molecule.
  • Expertise in Regenerative Medicine
    • Their leadership team combines extensive experience in materials science, orthopedics, drug delivery and venture to drive product innovation to the market.
  • Strong Intellectual Property
    • OsteoCure holds exclusive patents covering critical aspects of OCTA1, securing competitive positioning in bone regeneration therapeutics and pain.
  • Addressing Major Unmet Needs
    • OCTA1 directly targets a growing demand for minimally invasive, highly effective treatments for orthopedic conditions and injuries.

Meet the Co-Founders

From left to right:

Hunter Newman Ph.D. – Chief Executive Officer, Co-Founder

Shyni Varghese, Ph.D. – Chief Technology Officer, Co-Founder

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Join Today!

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.